Association between body mass index and breast cancer intrinsic subtypes in Japanese women

Kimura,Kosei; Tanaka,Satoru; Iwamoto,Mitsuhiko; Fujioka,Hiroya; Takahashi,Yuko; Satou,Nayuko; Uchiyama,Kazuhisa

doi:10.3892/etm.2012.621

Association between body mass index and breast cancer intrinsic subtypes in Japanese women

Authors:
- Kosei Kimura
- Satoru Tanaka
- Mitsuhiko Iwamoto
- Hiroya Fujioka
- Yuko Takahashi
- Nayuko Satou
- Kazuhisa Uchiyama
View Affiliations

Affiliations: Section of Breast and Endocrine Surgery, Department of General and Gastroenterological Surgery, Osaka Medical College, Osaka 569-8686, Japan
Published online on: June 25, 2012 https://doi.org/10.3892/etm.2012.621
Pages: 391-396

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to examine the association between body mass index (BMI) and breast cancer intrinsic subtypes in Japanese women. A more complete understanding of the subtypes of breast cancer may elucidate the mechanisms affecting the etiology and mortality associated with each subtype. Tumor data on 531 invasive breast cancer cases subtyped by estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (Her2) status were obtained [luminal A, luminal B, triple-negative (TN) and Her2‑type]. Demographics (age at diagnosis, menopausal status and BMI) were collected from medical records. Case‑only odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression, adjusting for age at diagnosis. Of the 531 cases, 333 (62.7%) were luminal A, 85 (16.0%) were luminal B, 43 (8.1%) were Her2-type and 70 (13.2%) were TN. Compared with luminal A cases, premenopausal TN cases were more likely to be obese (OR, 4.11; 95% CI, 1.10-14.40), while postmenopausal TN cases were more likely to be underweight (OR, 3.14; 95% CI, 1.19-8.01). Premenopausal luminal B cases were likely to be underweight or obese, while luminal B and Her2-type cases were likely to be underweight. In the present study, significant heterogeneity of associations between BMI and tumor subtypes was observed. Breast cancer subtypes may have various etiologies associated with each subtype.

View Figures

View References

1.	Masuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T; Japan Cancer Surveillance Research Group: Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol. 39:850–858. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Minami Y, Tsubono Y, Nishino Y, Ohuchi N, Shibuya D and Hisamichi S: The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer. 108:901–906. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar
5.	Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB and Caan BJ: Epidemiology breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 11:R312009. View Article : Google Scholar : PubMed/NCBI
6.	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, Blamey RW, Macmillan D and Ellis IO: Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 42:3149–3156. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
9.	Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR and Børresen-Dale AL: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 7:1272006.
10.	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar
11.	Brown M, Tsodikov A, Bauer KR, Parise CA and Caggiano V: The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999–2004. Cancer. 112:737–747. 2008.PubMed/NCBI
12.	Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ and Eley JW: The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 20:1071–1082. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Millikan RC, Newman B, Tse CK, et al: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 109:123–139. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Phipps AI, Malone KE, Porter PL, Daling JR and Li CI: Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 17:2078–2086. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, et al: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 16:439–443. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Iwasaki M, Otani T, Inoue M, Sasazuki S and Tsugane S; for the Japan Public Health Center-Based Prospective Study Group: Body size and risk for breast cancer in relation to estrogen and progesterone receptor status in Japan. Ann Epidemiol. 17:304–312. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, Shimazu T and Tsugane S; Japan Public Health Center-Based Prospective Study Group: Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status-the Japan public health center-based prospective study. Int J Cancer. 129:1214–1224. 2011.
18.	WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 363:157–163. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Begg CB and Zhang ZF: Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev. 3:173–175. 1994.PubMed/NCBI
20.	Rich-Edwards JW, Goldman MB, Willett WC, Hunter DJ, Stampfer ML, Colditz GA and Manson JE: Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol. 171:171–177. 1994. View Article : Google Scholar : PubMed/NCBI
21.	Harvie M, Hooper L and Howell AH: Central obesity and breast cancer risk: a systematic review. Obes Rev. 4:157–173. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S and Surmacz E: Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res. 12:1447–1453. 2006. View Article : Google Scholar : PubMed/NCBI
23.	Friedenreich CM: Review of anthropometric factor and breast cancer risk. Eur J Cancer Prev. 10:15–32. 2001. View Article : Google Scholar : PubMed/NCBI
24.	Renehan AG, Tyson M, Egger M, Heller RF and Zwahlen M: Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 371:569–578. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Miller WR, Hawkins RA and Forrest AP: Significance of aromatase activity in human breast cancer. Cancer Res. 42:3365s–3368s. 1982.PubMed/NCBI
26.	Perel E, Wilkins D and Killinger DW: The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue. J Steroid Biochem. 13:89–94. 1980. View Article : Google Scholar : PubMed/NCBI
27.	Sakakura T, Nishizuka Y and Dawe CJ: Capacity of mammary fat pads of adult C3H/HeMs mice to interact morphogenetically with fetal mammary epithelium. J Natl Cancer Inst. 63:733–736. 1979.PubMed/NCBI
28.	Sakakura T, Nishizuka Y and Dawe CJ: Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland. Science. 194:1439–1441. 1976. View Article : Google Scholar : PubMed/NCBI
29.	Shyamala G: Progesterone signaling and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia. 4:89–104. 1999. View Article : Google Scholar : PubMed/NCBI
30.	Kalkhoff RK: Metabolic effects of progesterone. Am J Obstet Gynecol. 142:735–738. 1982.PubMed/NCBI
31.	Russo J, Hu YF, Silva ID and Russo IH: Cancer risk related to mammary gland structure and development. Microsc Res Tech. 52:204–223. 2001. View Article : Google Scholar : PubMed/NCBI
32.	Prat A and Perou CM: Mammary development meets cancer genomics. Nat Med. 15:842–844. 2009. View Article : Google Scholar : PubMed/NCBI